6th International Symposium on Hepatitis Care in Substance Users, 6th Sept 2017 An international conference bringing together hepatitis C experts from around the world is today calling for strategies to prioritise people who use drugs, saying hepatitis C elimination is impossible without them. “The number of people around the world dying from hepatitis C is increasing. We have the tools to...
2nd World Indigenous Peoples Conference on Viral Hepatitis, August 2017 The Anchorage Statement is a statement on Indigenous Peoples and Viral Hepatitis, which was prepared by Indigenous peoples globally who attended the 2nd World Indigenous Peoples Conference on Viral Hepatitis held in Anchorage Alaska in August 2017. The Anchorage Statement sets out the aspirations of Indigenous peoples...
The Conversation, July 31, 2017 4.05pm AEST The World Health Organisation recently set ambitious goals for the “elimination of hepatitis C as a major public health threat”. These included having 80% of people treated and an 80% reduction in the spread of the virus by 2030. Given there are around 70 million people infected with hep C worldwide, only 20% diagnosed, and no effective vaccine, the...
Merck Sharp & Dohme According to estimates, Australia can completely eradicate hep C in about 10 years. But your involvement is needed. This practical webinar will allow you to gain knowledge and get involved in this important public health initiative. After attending this webinar, you should be able to: Understand benefits of highly effective new hep C treatments for your patients...
Joint position statement, Australia, June 2017 This joint Position Statement aims to strongly refute and reject the findings of the Cochrane Review report titled Direct-acting antivirals for chronic hepatitis C, published by the Cochrane Hepato‐Biliary Group on 6 June 2017. The Position Statement was prepared by the expert panel who published a Consensus Statement for Australian recommendations...
Kirby Institute/UNSW – 21 February 2017
More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby Institute at UNSW Sydney.
Read more here
Download report (PDF) here